Showing results (231-240 of 376) with videos related to

Sort By:
Pageof 38
Enfermedades Infecciosas Y Microbiologia Clinica|October 5, 2010
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]Josep M Llibre, Antonio Antela, José Ramón Arribas, et al.
Journal of the International AIDS Society|November 15, 2014
Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patientsDaniel Podzamczer, Jhon Fredy Rojas, Isabel Neves, et al.
Current HIV Research|June 19, 2009
PPARgamma Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophyMaria Saumoy, Sergi Veloso, Carlos Alonso-Villaverde, et al.
The Lancet. Infectious Diseases|December 4, 2025
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trialGeorg M N Behrens, Lambert Assoumou, Geoffroy Liegeon, et al.
Antiviral Therapy|February 1, 2012
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week studyJosep M Llibre, Maria J Buzón, Marta Massanella, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretroviralsArkaitz Imaz, Josep M Llibre, Marta Mora, et al.
AIDS Research and Human Retroviruses|September 22, 2010
No relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysisSergi Veloso, Montserrat Olona, Joaquim Peraire, et al.
Open Forum Infectious Diseases|May 18, 2016
Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient CharacteristicsJuan Berenguer, Antonio Rivero, Inmaculada Jarrín, et al.
Journal of the International AIDS Society|November 15, 2014
Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART StudyAna Carrero-Gras, Antonio Antela, Jessica Muñoz-Rodríguez, et al.
Nature Medicine|March 16, 2010
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsMaria J Buzón, Marta Massanella, Josep M Llibre, et al.
Pageof 38